Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human PCSK9 (R194A) Protein, His Tag, 50µg  

Recombinant Human PCSK9 (R194A) Protein, His Tag, 50µg

Recombinant Human PCSK9 (R194A) Protein, Gln 31 - Gln 692, produced in human 293 cells (HEK293), His Tag

Synonym
recombinant, human, protein, PCSK9,PC9

More details

PCA-H5226-50

Availability: within 7 days

312,00 €

Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene.This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

Source
Recombinant Human PCSK9 (R194A), His Tag (PCA-H5226) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Gln 692 (Accession # AAI166619.1).
Predicted N-terminus: Gln 31

Molecular Characterization
This protein is fused with a polyhistidine tag at the C-terminus. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 58.0 kDa respectively. The protein migrates as 17 kDa and 66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The R194A mutation results in lower affinity of PCSK9 for LDLR.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).
 
Bioactivity
Please refer to product data sheet.

References

(1) Seidah NG, et al., 2003, Proc. Natl. Acad. Sci. U.S.A. 100 (3): 928–33.
(2) Abifadel, M. et al., 2003, Nat. Genet. 34: 154-156.
(3) Dubuc G. et al., 2004, Arterioscler. Thromb. Vasc. Biol. 24 (8): 1454–9.